Education
About Us
Working with TipRanks
Follow Us
Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
Total Valuation
Bafna Pharmaceuticals Limited has a market cap or net worth of ₹1.81B. The enterprise value is ―.
Market Cap₹1.81B
Enterprise Value―
Share Statistics
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,656,336
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bafna Pharmaceuticals Limited’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 22.16%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)22.16%
Return on Capital Employed (ROCE)0.25
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover1.03
Inventory Turnover3.61
Valuation Ratios
The current PE Ratio of Bafna Pharmaceuticals Limited is 25.80. Bafna Pharmaceuticals Limited’s PEG ratio is 0.05.
PE Ratio25.80
PS Ratio0.00
PB Ratio2.30
Price to Fair Value2.35
Price to FCF37.90
Price to Operating Cash Flow37.96
PEG Ratio0.05
Income Statement
In the last 12 months, Bafna Pharmaceuticals Limited had revenue of 1.52B and earned 73.48M in profits. Earnings per share was 3.11.
Revenue1.52B
Gross Profit455.58M
Operating Income237.66M
Pretax Income73.48M
Net Income73.48M
EBITDA146.34M
Earnings Per Share (EPS)3.11
Cash Flow
In the last 12 months, operating cash flow was 50.24M and capital expenditures 0.00, giving a free cash flow of 50.24M billion.
Operating Cash Flow50.24M
Free Cash Flow50.24M
Free Cash Flow per Share2.12
Dividends & Yields
Bafna Pharmaceuticals Limited pays an annual dividend of ₹0.6, resulting in a dividend yield of ―
Dividend Per Share₹0.6
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change-20.02%
50-Day Moving Average77.20
200-Day Moving Average79.82
Relative Strength Index (RSI)51.99
Average Volume (3m)585.00
Important Dates
Bafna Pharmaceuticals Limited upcoming earnings date is May 30, 2025, TBA Not Confirmed.
Last Earnings DateFeb 6, 2025
Next Earnings DateMay 30, 2025
Ex-Dividend DateSep 19, 2013
Financial Position
Bafna Pharmaceuticals Limited as a current ratio of 1.75, with Debt / Equity ratio of 22.75%
Current Ratio1.75
Quick Ratio1.20
Debt to Market Cap0.13
Net Debt to EBITDA1.57
Interest Coverage Ratio10.38
Taxes
In the past 12 months, Bafna Pharmaceuticals Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bafna Pharmaceuticals Limited EV to EBITDA ratio is 14.53, with an EV/FCF ratio of -33.41.
EV to Sales1.39
EV to EBITDA14.53
EV to Free Cash Flow-33.41
EV to Operating Cash Flow22.41
Balance Sheet
Bafna Pharmaceuticals Limited has ₹13.96M in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹13.96M billion.
Cash & Marketable Securities₹13.96M
Total Debt₹0.00
Net Cash-₹13.96M
Net Cash Per Share-₹0.59
Tangible Book Value Per Share₹33.47
Margins
Gross margin is 20.41%, with operating margin of 15.59%, and net profit margin of 4.82%.
Gross Margin20.41%
Operating Margin15.59%
Pretax Margin4.82%
Net Profit Margin4.82%
EBITDA Margin9.60%
EBIT Margin6.09%
Analyst Forecast
The average price target for Bafna Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―